| Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... The Lancet 397 (10271), 281-292, 2021 | 153 | 2021 |
| EXTL3 mutations cause skeletal dysplasia, immune deficiency, and developmental delay S Volpi, Y Yamazaki, PM Brauer, E van Rooijen, A Hayashida, ... Journal of Experimental Medicine 214 (3), 623-637, 2017 | 82 | 2017 |
| Genomic instability of osteosarcoma cell lines in culture: impact on the prediction of metastasis relevant genes R Muff, P Rath, RM Ram Kumar, K Husmann, W Born, M Baudis, B Fuchs PloS one 10 (5), e0125611, 2015 | 53 | 2015 |
| An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) DL Clouthier, SC Lien, SYC Yang, LT Nguyen, VSK Manem, D Gray, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 49 | 2019 |
| Progenetix: 12 years of oncogenomic data curation H Cai, N Kumar, N Ai, S Gupta, P Rath, M Baudis Nucleic acids research 42 (D1), D1055-D1062, 2014 | 45 | 2014 |
| Epigenomic, genomic, and transcriptomic landscape of schwannomatosis S Mansouri, S Suppiah, Y Mamatjan, I Paganini, JC Liu, S Karimi, V Patil, ... Acta neuropathologica 141, 101-116, 2021 | 28 | 2021 |
| Minimalist approaches to cancer tissue-of-origin classification by DNA methylation D Xia, AJ Leon, M Cabanero, TJ Pugh, MS Tsao, P Rath, LLY Siu, C Yu, ... Modern Pathology 33 (10), 1874-1888, 2020 | 25 | 2020 |
| arrayMap 2014: an updated cancer genome resource H Cai, S Gupta, P Rath, N Ai, M Baudis Nucleic acids research 43 (D1), D825-D830, 2015 | 19 | 2015 |
| Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer JI Weberpals, TJ Pugh, P Marco‐Casanova, GD Goss, N Andrews Wright, ... Cancer Medicine 10 (9), 3045-3058, 2021 | 12 | 2021 |
| Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer A Madariaga, S Garg, JP Bruce, S Thiryayi, V Mandilaras, P Rath, AM Oza, ... Gynecologic Oncology 159 (2), 539-545, 2020 | 8 | 2020 |
| Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities S Suppiah, S Mansouri, Y Mamatjan, JC Liu, MM Bhunia, V Patil, P Rath, ... Nature communications 14 (1), 2696, 2023 | 6 | 2023 |
| Tumor molecular profiling to differentiate extreme responses to first-line platinum-based chemotherapy in suboptimally debulked serous ovarian cancer patients. JI Weberpals, T Pugh, GD Goss, B Lo, N Andrews Wright, L Bernard, ... Journal of Clinical Oncology 36 (15_suppl), 5561-5561, 2018 | 2 | 2018 |
| Gemcitabine plus adavosertib for platinum-resistant/refractory recurrent ovarian cancer: A randomised placebo-controlled trial S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... Lancet (London, England) 397 (10271), 281, 2021 | | 2021 |
| Mt Receptor D Actinomycin, S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... Lancet 397, 281-92, 2021 | | 2021 |
| EPCO-04. GENOMIC AND EPIGENOMIC HALLMARKS OF SCHWANNOMATOSIS SCHWANNOMAS S Mansouri, S Suppiah, Y Mamatjan, I Paganini, J Liu, S Karimi, V Patil, ... Neuro-Oncology 22 (Suppl 2), ii69, 2020 | | 2020 |
| Biomarkers of outcome with weekly paclitaxel in platinum-resistant high-grade serous or endometrioid ovarian carcinoma A Madariaga, S Garg, J Bruce, P Rath, V Mandilaras, S Thiryayi, AM Oza, ... Gynecologic Oncology 159, 149, 2020 | | 2020 |
| 13. Bioinformatics and interpretation for clinical reporting of an integrated whole genome and transcriptome assay A Fortuna, P Rath, A Leon, X Luo, Y Sundaravadanam, P Ruzanov, ... Cancer Genetics 244, 5-6, 2020 | | 2020 |
| Cc 5013 is a more potent molecular analog of thalidomide. Menu S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... | | |
